
David Belluck
General Partner
David Belluck General Partner
David has 30 years of experience investing in and working with lower middle market companies at Riverside Partners, where he has been a General Partner since 1992. David is Chair of the Advisory Board of America Forward. He serves on the National Advisory Board for Public Service at Harvard College and on the Board of Advisors of the Tisch College for Civic Life at Tufts University. David formerly served as Chair of Cool Globes Boston and was formerly a member of the Governor’s Council of Economic Advisors.
David holds a Bachelor of Arts degree in Economics, magna cum laude, from Harvard College, and a Master of Business Administration, with distinction, from Harvard Business School.

Steve Kaplan
General Partner
Steve Kaplan General Partner
Steve has more than 35 years of private equity, strategy consulting, and operating experience. He joined Riverside Partners as a General Partner in 2006.
Previously, Steve was a Managing Director of Audax Group, a private equity and mezzanine debt firm, and served as an Operating Partner at Texas Pacific Group. His operating experience includes serving as President of Harris Graphics, a $450 million printing press manufacturer, Executive Vice President and CFO of The Coleman Company, a $1.2 billion manufacturer of outdoor recreation equipment, and Executive Vice President, CFO, and CSO of AM International, a $1.2 billion graphic arts equipment and supplies manufacturer. Steve began his career in strategy consulting and was a Partner at The Boston Consulting Group.
Steve holds Bachelor’s degrees in Electrical Engineering and Computer Science and in Management Science from MIT as well as a Master’s degree in Management from Sloan School at MIT.

Craig Stern
General Partner
Craig Stern General Partner
Craig brings 22 years of private equity and operations experience to the Riverside team, which he joined in 2012 as a Vice President.
Prior to joining Riverside, Craig was Vice President, Corporate Development at Nextag, Inc., a technology and e-commerce company, where he led the sourcing and completion of acquisitions in the U.S. and Europe. Before joining Nextag, he was a Vice President at Providence Equity Partners, where he focused on technology and media investments. Prior to Providence Equity, Craig was an investment professional at General Atlantic Partners, where he focused on investments in software, technology-enabled services, and digital media businesses. Before General Atlantic, he worked in the telecommunications group within the investment banking division of Morgan Stanley.
Craig holds a Bachelor of Arts degree in Economics and East Asian Studies, with honors, from Harvard College, and a Master of Business Administration from Harvard Business School.

Patrick Furlong
Partner
Patrick Furlong Partner
Patrick has more than 15 years of private equity and finance experience. He joined Riverside Partners as a Vice President in 2016.
Prior to Riverside, Patrick was an investment professional at Enhanced Healthcare Partners, a healthcare services focused private equity firm, and Flexpoint Ford, a healthcare and financial services focused private equity firm. Patrick previously worked at Bank of America in the healthcare investment banking group.
Patrick holds a Bachelor of Arts degree in Biology and Economics, summa cum laude, from the University of Pennsylvania, and a Master of Business Administration from Harvard Business School.

Michael Magliochetti, PhD
Operating Partner
Michael Magliochetti, PhD Operating Partner
Mike had served as a Healthcare Advisory Board member prior to joining Riverside in 2012 to focus on the Firm’s healthcare investment activity. He brings 28 years of successful healthcare operating and acquisition experience to Riverside.
Prior to joining Riverside, Mike served as CEO of Claros Diagnostics, a point-of-care in-vitro diagnostic firm, which was honored as one of the Top 50 Most Innovative Companies in the World for 2011 by MIT Technology Review, and acquired by OPKO Health. He previously served as CEO of RMH, a leading orthopedic products company, and as CEO of both HemaMetrics and UroSurge. He has held senior positions with the medical device company Haemonetics and the polymer products company Delta Surprenant, and has completed an assignment with the U.S. Army Research Command. In addition to serving on the Board of Overseers for Boston Museum of Science, Advisory Boards for Boston Children’s Hospital, Lahey Clinic and Medical Development Group-Boston, Mike has also served as an Adjunct Professor of Biomedical Engineering at the University of Iowa and consulted with several medical device and pharmaceutical companies.
Mike holds a Bachelor of Science degree in Chemical Engineering and a Master of Business Administration from Northeastern University, and a Ph.D. in Chemical Engineering from the University of Massachusetts at Amherst.

Brian Guthrie
Senior Advisor
Brian Guthrie Senior Advisor
Brian has 28 years of experience working with and investing in lower middle market companies at Riverside, where he became a General Partner in 1992.
Prior to Riverside, Brian worked at Monitor Group, a business strategy consulting firm. He also has served as a director of the Boston chapter of the Association for Corporate Growth.
Brian holds a Bachelor of Arts degree in Economics, cum laude, from Harvard College.

Alicia Alexander
Principal
Alicia Alexander Principal
Alicia brings over 13 years of private equity and investment banking experience to the Riverside team, which she joined in 2024 as a Principal.
Prior to joining Riverside, Alicia worked at Audax Private Equity where she focused on investments across a range of industries. Before Audax, she worked in private equity at Webster Equity Partners and LaSalle Capital Group. Alicia previously worked at Bank of America Merrill Lynch in the Consumer and Retail investment banking division.
Alicia holds both a Bachelor of Business Administration and Bachelor of Arts from the University of Notre Dame, and a Master of Business Administration from Harvard Business School.

Joshua Griffin
Principal
Joshua Griffin Principal
Josh joined Riverside Partners in 2026 as a Principal, bringing over 13 years of private equity and investment banking experience.
Prior to joining Riverside, Josh was a Principal at Webster Equity Partners, a healthcare services focused private equity firm, where he led investments across multiple healthcare subsectors. Earlier in his career, Josh worked in healthcare investment banking at Greenhill & Co. and Cain Brothers and began his career as an analyst at Bank of America Merrill Lynch.
Josh holds a Bachelor of Business Administration from Temple University and a Master of Business Administration from the Stern School of Business at New York University.

Andrew Perkins
Principal
Andrew Perkins Principal
Andrew brings eight years of private equity and investment banking experience to the Riverside team, which he joined in 2019 as an Associate.
Prior to joining Riverside, Andrew was an Associate in the healthcare group at Barclays, where he was involved in executing a variety of M&A and financing transactions. Previously, he was an Analyst in the firm’s healthcare equity capital markets group.
Andrew holds an Honors Bachelor of Arts degree in Accounting, cum laude, from College of the Holy Cross.

Stephen Mattingly
Senior Associate
Stephen Mattingly Senior Associate
Stephen brings six years of investment banking and private equity experience to the Riverside team, which he joined in 2023 as an Associate.
Prior to joining Riverside, Stephen worked as both an Associate and an Analyst at AGC Partners, where he was involved in executing over 15 M&A transactions for software and tech-enabled services businesses.
Stephen holds a Bachelor of Arts in Economics with a minor in Business Institutions from Northwestern University.

Ben Wen
Associate
Ben Wen Associate
Ben brings two years of investment banking experience to the Riverside team, which he joined in 2023 as an Associate.
Prior to joining Riverside, Ben was an Analyst at Jefferies Technology Group in San Francisco, where he was involved in executing a variety of M&A and financing transactions.
Ben holds a Bachelor of Science degree in Business with a concentration in Finance from Babson College.

Noah Lawrence
Associate
Noah Lawrence Associate
Noah brings two years of investment banking experience to the Riverside team, which he joined in 2024 as an Associate.
Prior to joining Riverside, Noah worked as an Analyst at Aeris Partners, where he was involved in executing a variety of M&A transactions for Software and HCIT businesses.
Noah holds a Bachelor of Science degree in Management, with concentrations in Finance and Accounting, from the Carroll School of Management at Boston College.

Sam Weber
Associate
Sam Weber Associate
Sam brings two and a half years of investment banking experience to the Riverside team, which he joined in 2024 as an Associate.
Prior to joining Riverside, Sam worked as both an Associate and an Analyst at AGC Partners, where he was involved in executing over 8 M&A transactions for software and tech-enabled services businesses.
Sam holds a Bachelor of Arts in Economics from the University of Michigan.

Pierce Leveillee
Associate
Pierce Leveillee Associate
Pierce brings two and a half years of investment banking experience to the Riverside team, which he joined in 2025 as an Associate.
Prior to joining Riverside, Pierce worked as both an Associate and an Analyst at AGC Partners, where he was involved in executing a variety of M&A transactions for software and tech-enabled services businesses.
Pierce holds a Bachelor of Science in Finance, with High Distinction, from the Kelley School of Business at Indiana University.

Kevin Sullivan
Chief Financial Officer & Chief Compliance Officer
Kevin Sullivan Chief Financial Officer & Chief Compliance Officer
Kevin has 25 years of experience in accounting and finance.
Prior to joining Riverside in 2006, Kevin was a Senior Controller at Thomas H. Lee Partners, a Boston based private equity firm. Prior to this, he was the Director of Finance for Exa Corporation, a venture-backed company which develops and markets fluid flow simulation software. Kevin began his career as a Certified Public Accountant at PricewaterhouseCoopers in the firm’s audit practice.
Kevin holds a Bachelor of Arts degree in Economics from Columbia University, and a Master of Science in Accounting from Northeastern University.

Erica Edson
Director of Administration
Erica Edson Director of Administration
Erica joined Riverside Partners in 2002 as an Executive Assistant.
Prior to joining Riverside, Erica was Office Manager at Redleaf Group, an early stage venture capital firm, and Portfolio Assistant at Triumph Capital Group, a private equity firm. Erica began her career as an Executive Assistant at Colonial Management Associates.
Erica holds a Bachelor of Arts degree in English from Keene State College.

Meg Wortley
Executive Assistant/Front Office Coordinator
Meg Wortley Executive Assistant/Front Office Coordinator
Prior to joining Riverside in 2021, Meg was a Personal Assistant/Household Manager in Wellesley, MA. Meg has had a career in private households in California, Hawaii, Maryland, New York and the Cayman Islands.
Meg holds a Bachelor of Science in Elementary Education from The College of St Rose.

Eli J. Segal
January 15, 1943 – February 20, 2006
Eli J. Segal January 15, 1943 – February 20, 2006
Riverside Partners remembers our friend and partner, Eli Segal. Eli was a successful businessman, a dedicated public servant and a devoted family man. At Riverside, Eli was a cherished mentor, advisor and friend to everyone on our team. We will miss his friendship and partnership dearly.
Donald Berwick, MD Former Administrator of CMS | Faculty of HMS, Harvard Medical School
Dr. Berwick, a pediatrician by training, is President Emeritus and Senior Fellow at the Institute for Healthcare Improvement, which he co-founded and led for 19 years. He is the former Administrator of the Centers for Medicare and Medicaid Services, appointed by President Obama. Dr. Berwick obtained his bachelor’s from Harvard College and earned an M.D. from Harvard Medical School and an M.P.P. from John F. Kennedy School of Government. He has served on the faculties of the Harvard Medical School (where he is currently a Lecturer in the Department of Health Care Policy) and the Harvard School of Public Health.
Vita Cassese Former Chief Information Officer, Pfizer
Ms. Cassese has over 30 years of operations experience at Pfizer Inc., a $67 billion Fortune 30 company. She has served as a member of multiple boards in the Pharmaceutical Industry. Ms. Cassese holds a bachelor’s in Mathematics from the College of Mount Saint Vincent and a master’s of business administration from New York University’s Stern School of Business.
Jeremy P. Goldberg Former Senior Operating and Business Development Executive, Endo Pharma
Mr. Goldberg is an experienced healthcare/pharmaceutical deal maker with a combination of operating/financial/transactional/business development experience in companies from start-ups to $1 Billion+ sales-operating companies. He currently serves on the Dana Farber Cancer Institute Visiting Committee, NIH/Cambridge/Oxford International Biomedical Alliance board, and Einstein Health Network board.
John D. Halamka, MD President - Mayo Clinic Platform, Former CIO - Beth Israel Deaconess, Former CIO - Harvard Medical School,
Dr. Halamka serves as President of the Mayo Clinic Platform, a group of digital and long-distance health care initiatives encompassing a coordinated portfolio approach to create new platform ventures to take advantage of emerging technologies such as AI, connected healthcare devices, and natural language processing. Trained in emergency medicine and medical informatics, John has been developing and implementing health care information strategy and policy for more than 25 years. He specializes in AI, the adoption of EHRs and the secure sharing of healthcare data for care coordination, population health, and quality improvement. In 2020, he was elected to the National Academy of Medicine (NAM). Dr. Halamka previously served as the Chief Information Officer (CIO) at Beth Israel Deaconess System, Chairman of the New England Healthcare Exchange Network (NEHEN), and a practicing emergency physician. He also serves as Professor of International Healthcare Innovation at Harvard Medical School.
Dr. Halamka completed his undergraduate studies at Stanford University, where he received degrees in Medical Microbiology and a Public Policy with a focus on technology issues. He attended medical school at the University of California, San Francisco and simultaneously pursued graduate work in Bioengineering at the University of California, Berkeley focusing on technology issues in medicine. He completed his residency at Harbor–UCLA Medical Center in the Department of Emergency Medicine.
Chip Hance Former CEO, Creganna-Tactx
Mr. Hance served as President and CEO of Creganna Medical through its acquisition by TE Connectivity. He was previously Senior Vice President of the Vascular Division at Abbott and President of Abbott’s Diabetes Care business. Mr. Hance earned a bachelor’s in Chemical Engineering from the Massachusetts Institute of Technology and master’s of business administration from Harvard Business School.
Julie Klapstein Former Founder and CEO, Availity
Ms. Klapstein has been a senior executive and CEO at multiple healthcare IT companies and is on the board of BLS, Amedisys, QSI (NextGen), eSolutions, and Dominion Diagnostics. She was the founding CEO of Availity LLC. Ms. Klapstein earned her bachelor’s from Portland State University in Portland, Oregon.
Mary Mirabelli Senior Vice President, Healthcare Financial Management Association (HFMA) | Hewlett Packard Global Healthcare Practice
Ms. Mirabelli currently serves as the Vice President of Hewlett Packard Enterprise’s Global Healthcare Practice. She previously served as National Chair for the Healthcare Financial Management Association (HFMA) and as a senior executive at Hospital Corporation of America (HCA). She received a master’s of management from the J.L. Kellogg Graduate School of Management, Northwestern University and bachelor’s in Occupational Therapy from the University of Illinois.
Caroline Popper, MD, MPH Founder/President, Popper and Company
Dr. Popper is Founder and President of Popper and Company, a boutique life sciences consulting firm. She has 25 years of hands-on biotech/life sciences operating experience. An internist and pathologist, she combines this perspective with that gained from managing a wide spectrum of life sciences businesses in diagnostics, devices, and drug discovery. She received an M.D. from University of the Witwatersrand, South Africa, and served as internist and pathologist at Johns Hopkins University. Dr. Popper was also trained in Health Policy and Economics at the Johns Hopkins Bloomberg School of Public Health.
David J. Shulkin, MD , Former Secretary of the US Department of Veterans Affairs
The Honorable Dr. David J. Shulkin was the ninth Secretary of the US Department of Veterans Affairs. Previously, he served as chief executive of leading hospitals and health systems including Beth Israel in New York City and Morristown Medical Center in Northern NJ, as well as the Chief Medical Officer of the University of Pennsylvania Health System, the Hospital of the University of Pennsylvania, Temple University Hospital, and the Medical College of Pennsylvania Hospital. Dr. Shulkin founded and served as the Chairman and CEO of DoctorQuality, one of the first consumer orientated sources of information for quality and safety in healthcare. He received his medical degree from the Medical College of Pennsylvania, his internship at Yale University School of Medicine, and a residency and Fellowship in General Medicine at the University of Pittsburgh Presbyterian Medical Center.
Christine Shuster CEO of Emerson Hospital and Chair of the Massachusetts Health & Hospital Association (MHA) Board of Trustees, Emerson Hospital
Ms. Schuster is the President and CEO of Emerson Hospital, Inc. She previously served as President and CEO of Quincy Medical Center Inc. Ms. Schuster received a master’s of business administration from the University of Chicago Graduate School of Business and a bachelor’s in Nursing from Boston University.
David Strand Former COO, Cleveland Clinic
Mr. Strand has spent more than 30 years providing executive leadership to some of the nation’s leading health care institutions. He served as CEO of a number of early stage companies, including ExperiaHealth. He also served as COO of the Cleveland Clinic; COO of Allina Health System, a leading integrated health system; and CEO of Medica, one of the nation’s largest and most reputable health plans. David received his bachelor’s from Gustavus Adolphus College and his J.D. from the University of Minnesota. David currently serves on the boards of Riverside Partners, the San Francisco Symphony, and La Luz.
Mark Zitter Founder and Chair, Zetema Project
Mr. Zitter is Founder and Chair of the Zetema Project, a panel of healthcare leaders from the political left and right as well as all the major industry segments, whose goal is to inform the national healthcare conversation. He is the CEO and Founder of Zitter Health Insights, a market research and data firm focused on access to prescription drugs. He also was the founding CEO and Chairman of Vital Decisions, a telephone counseling service for patients with life-limiting illness. Mr. Zitter holds a bachelor’s from Wesleyan University and a master’s of business administration from Stanford University.
Jeff Hargroves Founder, ProPharma Group
Jeff founded ProPharma Group in 2001 to create a company that would partner with clients to provide compliance-related services for long-term solutions. ProPharma Group became a leading provider of regulatory and compliance services to pharmaceutical, biotechnology and medical device customers for clients from early concept development through each clinical phase, product launch, and commercialization. The Company's primary service offerings include regulatory affairs, life science consulting, pharmacovigilance and medical information services. The company grew to 1,200 employees with 5 US-based offices and 10 additional offices across Canada, UK, Netherlands, Sweden, Germany, Japan and Australia. ProPharma was acquired by Odyssey Investment Partners in 2020. Prior to ProPharma, Jeff served in leadership roles with Ivy Animal Health, ALZA, BES Company and Coopers-Pittman Moore. Jeff earned a B.S. in Computer Engineering and B.S. in Electrical Engineering from the University of Missouri.
Jason Arcediano Chief Business Officer, Multiply Labs
Jason Arcediano serves as Chief Business Officer at Multiply labs. Previously, Jason was the SVP Business Development at AGC Biologics, a leading global Contract Development and Manufacturing Organization (CDMO). He also served as General Manager and VP Americas for Rentschler Bio-Pharma Inc. Jason earned a B.S. in Neuroscience at University of California, San Diego.
Rick Riegel Former CEO, Phlexglobal
Mr. Riegel is the former Chief Executive Officer of Phlexglobal and the former Chief Executive Officer of Liquent (sold to Parexel in 2012), which was a portfolio investment for Marlin Equity Partners and today is a division of Parexel. He has more than 25 years of management experience in executive, sales, and practice leadership positions with technology and professional services firms serving the needs of pharmaceutical and life sciences organizations. Mr. Riegel currently serves on the Board of Directors of IRISS, an industry consortium focused on the successful implementation of electronic submission standards in the life sciences industry.
Mike Lehmann Former President Global Pharma Development Services and Chief Commercial Officer, Patheon
Bankim Patel Former Executive Director of Capital Projects at Moderna, Moderna
Bankim is a 35-year veteran of the pharma/biotech industry. Prior to retiring, he most recently served as Executive Director of Capital Projects at Moderna for which he previously held roles as Senior Director of GMP and Capital Projects and Senior Director of Facilities, Engineering, and Validation. In his most recent role, Bankim was instrumental in the production of the COVID-19 vaccine. He led the projects to create additional production space which enabled the facility to deliver over 600 million doses during the first year of production, while also leading the maintenance and engineering organization based in Norwood, MA. During this time, he increased the staff from just himself to over 100 employees.
Previously Bankim served as Senior Director of Facilities and Engineering at Alexion Pharmaceuticals; VP of Facilities, Engineering, and Validation at ImClone Systems, a wholly owned subsidiary of Eli Lilly; and Director of Technical Services at Bristol-Myers Squibb. During his career, Bankim led capital projects to create production facilities, research facilities, office buildings, parking garages, vivarium, etc. with expenditures over $300 million. His experience includes over 15 years of operational leadership including maintenance, calibration, office services, EHS, and security and validation groups.
Bankim earned a B.S. in Mechanical Engineering from Rutgers University.
Robert Coughlin Former CEO of Massachusetts Biotechnology Council, JLL
Bob is a Managing Director at JLL and is the New England’s Life Science Practice Group lead. He specializes in the representation of lab, GMP manufacturing and technology space. Bob most recently operated as the CEO of the Massachusetts Biotechnology Council, where his mission was to advance Massachusetts’s leadership in the life sciences to grow the industry. He has also held senior executive positions in the environmental services, capital management and venture capital industries.
Bob has spent his career in both the public and private sectors. Before joining MassBio, he served as the Undersecretary of Economic Development within Governor Deval Patrick’s administration, where he prioritized both healthcare and economic development issues and was a strong advocate for the life sciences industry in Massachusetts. Prior to that, he was elected as State Representative to the 11th Norfolk District of Massachusetts for three terms.
In 2011, the American Diabetes Association honored Bob with their Father of the Year Award. In 2012, the Cystic Fibrosis Foundation honored Bob with the CF Foundation Volunteer Leadership Award and in 2013 he received the Boston Irish Business Award from the Boston Irish Business Association. In 2014, he was awarded for his leadership in Biotechnology by the Massachusetts Society for Medical Research. He received the NTSAD advocate of the year in 2015 and was named to the Boston Business Journal’s Power 50 and Top 50 Most Influential Bostonians. In 2016, he was honored with the Boston Biotech CEO Lifetime Achievement Award. His latest honors include the first-ever awarded Governor Paul Cellucci Fatherhood Award from the Children’s Trust and the Breath of Life Award from the Cystic Fibrosis Foundation (2017).
Robert is a graduate of the Massachusetts Maritime Academy where he majored in Marine Engineering and served as an officer in the United States Naval Reserve.
Lenny Herold Co-Founder, Corsis
Lenny has amassed over 25 years of experience in the technology industry, honing his skills while managing infrastructure at scale for numerous large media companies in New York City. He has managed both co-located and cloud-based environments at scale, navigated numerous mergers and acquisitions, datacenter consolidations, and high-profile deployments. He's passionate about automation, configuration management and virtualization.
In 2010, Lenny co-founded Corsis, a highly regarded technology advisory firm that provides services to the private equity sector. At Corsis, he played a critical role in developing the methodology the company utilized to assess and gauge the effectiveness of technology systems during due diligence. He spearheaded hundreds of evaluations covering diverse areas such as architecture, software development, infrastructure, and security. In 2020, Falfurrias Capital Partners acquired Corsis.
Lenny earned a B.S. in Telecommunications from the University of Florida.
Ed Benz, MD President and Chief Executive Officer Emeritus, Dana-Farber Cancer Institute
Dr. Benz is President and CEO Emeritus of the Dana-Farber Cancer Institute and is the Richard and Susan Smith Distinguished Professor of Medicine and Faculty Dean Emeritus for Oncology at Harvard Medical School. Dr. Benz has served as Chief of Hematology at Yale and Chief of Medicine at the University of Pittsburgh School of Medicine. He was the Physician-in-Chief at the Johns Hopkins Hospital and previously was a member of the Board of the Massachusetts Life Science Council. Dr. Benz is a graduate of Princeton and Harvard Medical School and received his training in internal medicine and hematology at Brigham and Women's Hospital, Boston Children’s Hospital, the National Institutes of Health and Yale University School of Medicine.
John Libertino, MD Senior Vice President, Emerson Hospital
Dr. Libertino currently serves as SVP of Emerson Hospital and Professor of Urology at Tufts University School of Medicine. He previously served as CEO, Director of the Cancer Center, Chair of Surgery, and Chair of Urology at Lahey Hospital and Medical Center. Dr. Libertino received his M.D. degree from the Georgetown University School of Medicine, where he also was an NIH fellow in cardiovascular research. He completed his residency in Urology at the Yale University School of Medicine, where he also served as a Harvey Cushing fellow in Surgery.
Deborah Nagle, MD Former Chief, Colorectal Surgery, Beth Israel Deaconess Medical Center
Dr. Nagle is Medical Director, Endomechanical and Surgical Oncology for Ethicon Inc., a Johnson & Johnson Company. Previously, she served as Chief, Colorectal Surgery at Beth Israel Deaconess Medical Center in Boston. She received an M.D. from the Perelman School of Medicine at the University of Pennsylvania.
Edward K. Rodriguez, MD, PhD Chief, Orthopedic Surgery, Beth Israel Deaconess Medical Center
Dr. Rodriguez is the Chief of the Division of Orthopedic Trauma at Beth Israel Deaconess Medical Center. He received a bachelor’s in Engineering and master’s in Biomedical Engineering from Johns Hopkins University. He completed a Ph.D. in Bioengineering at the University of California, San Diego, and received an M.D. from Harvard Medical School.
Peter Rosenblatt, MD Director, Urogynecology/Pelvic Reconstructive Surgery, Boston Urogynecology Associates at Mt. Auburn Hospital
Dr. Rosenblatt is the Director of Urogynecology and Pelvic Reconstructive Surgery at Mount Auburn Hospital, as well as an Assistant Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School. He received his undergraduate degree at Brown University, and an M.D. from Tufts University School of Medicine.
Christoph Wald, MD, PhD Professor & Chair, Department of Radiology at UMass Chan-Lahey; Vice Chair, Board of Chancellors of the American College of Radiology, Lahey Hospital and Medical Center
Dr. Wald currently serves as Chairman of the Department of Radiology, as well as President of the Medical Staff, at Lahey Hospital and Medical Center. He is a founding member of Rescue Lung, Rescue Life and has been the executive sponsor in radiology of the nationally renowned Lahey Lung Screening Program. Dr. Wald previously served as Vice Chair for the Department of Medical Education and Chair of the Graduate Medical Education Committee at the Lahey Clinic. He attended Rheinische Friedrich Wilhelms University, Rheinische Friedrich Wilhelms University Medical School and Aberdeen University Medical School. He has also earned a master’s of business administration from Babson College.
Stephen Zappala, MD Assistant Clinical Professor of Urology, Tufts University
Dr. Zappala is a Board-Certified Diplomat of the American Board of Urology, specializing in pediatric and adult urologic surgery, and also the Founder of Andover Urology. He currently serves as the Assistant Clinical Professor of Urology at Tufts University School of medicine and is a fellow at the American College of Surgeons. Dr. Zappala received a B.S. from Boston College and M.D. from University of Massachusetts Medical School.
John Keaney Jr., MD Chief, Division of Cardiovascular Medicine; Co-Executive Director, Heart and Vascular Center at Massachusetts General Brigham;, Professor of Medicine at Harvard Medical School
Dr. Keaney is Chief of the Division of Cardiovascular Medicine in the Department of Medicine at Brigham and Women’s Hospital and Executive Director of the Brigham Health Heart and Vascular Center.
Dr. Keaney received his medical degree from Yale University School of Medicine and trained in both Internal Medicine and Cardiovascular Medicine at Brigham and Women’s Hospital. Dr. Keaney is board certified in both internal medicine and cardiovascular medicine. Before returning to Brigham and Women’s Hospital, Dr. Keaney was Chief of Cardiovascular Medicine at the University of Massachusetts Medical School. Dr. Keaney’s clinical interests are in the treatment of acute coronary syndromes and valvular heart disease.
Dr. Keaney has authored over 230 publications is a recognized expert in the biology of blood vessels and is currently Associate Editor for the New England Journal of Medicine. Dr. Keaney is a frequent consultant to the National Institutes of Health in matters related to vascular health.
Mayank Agarwal Managing Principal - Strategy MA and Former Senior Director - EY-Parthenon,
Mayank has over 20 years of experience driving tech-enabled transformation in healthcare and life sciences, with a focus on revenue cycle, EHR, and M&A integration at top-tier firms incl. PwC and EY-Parthenon. He has led many AI-driven value creation strategies for PE-backed companies, bridging deep healthcare domain knowledge with practical AI implementation. In addition, Mayank oversaw a book of business, led client engagements, and provided thought leadership in technology-enabled M&A strategies. During his career, he has cultivated relationships with C-suite executives, led engagements from initiation to successful delivery, and shaped the approach to M&A strategies. He has led 25+ complex M&A transactions, value creation programs, and digital transformations. Mayank is a trusted partner to operating teams and C-suites. Today, he directs a team of expert consultants specializing in IT, Cybersecurity, AI, Data, and Software Products. Mayank earned a B.S. in Motivational Pathway.
Dimitris Agrafiotis, Ph.D. Former VP Digital Pfizer, Former CIO Novartis, Former VP Informatics J&J,
Dimitris is a respected thought leader, a published scientist, and an accomplished software architect, with extensive experience in building teams to support pharmaceutical R&D in biotech, large pharma, and the biopharmaceutical services industry. Dr. Agrafiotis previously served as Chief Digital Officer for Generate Biomedicines, Vice President of Digital for Pfizer, Chief Information Officer for the Novartis Institutes for Biomedical Research, Chief Data Officer & Head of Technology Products of Covance/Labcorp, and Vice President of Research and Early Development Informatics and IT of Johnson & Johnson (J&J). Prior to J&J, he spent ten years at biotech startup 3-Dimensional Pharmaceuticals, from its founding to its IPO and eventual acquisition by J&J. He started his career as a Senior Scientist in the Computer-Aided Drug Design group at Parke-Davis, which he joined following postdoctoral fellowships. He is the recipient of numerous awards and distinctions, including being elected Fellow of the Royal Society of Chemistry and named in Computerworld’s Premier 100 Technology Leaders.
Dimitris earned a B.S. from University of Patras, Ph.D. from Imperial College, University of London, and had postdoctoral fellowships at Harvard University and University of California, Berkeley.
John D. Halamka, MD President - Mayo Clinic Platform, Former CIO - Beth Israel Deaconess, Former CIO - Harvard Medical School,
Dr. Halamka serves as President of the Mayo Clinic Platform, a group of digital and long-distance health care initiatives encompassing a coordinated portfolio approach to create new platform ventures to take advantage of emerging technologies such as AI, connected healthcare devices, and natural language processing. Trained in emergency medicine and medical informatics, John has been developing and implementing health care information strategy and policy for more than 25 years. He specializes in AI, the adoption of EHRs and the secure sharing of healthcare data for care coordination, population health, and quality improvement. In 2020, he was elected to the National Academy of Medicine (NAM). Dr. Halamka previously served as the Chief Information Officer (CIO) at Beth Israel Deaconess System, Chairman of the New England Healthcare Exchange Network (NEHEN), and a practicing emergency physician. He also serves as Professor of International Healthcare Innovation at Harvard Medical School.
Dr. Halamka completed his undergraduate studies at Stanford University, where he received degrees in Medical Microbiology and a Public Policy with a focus on technology issues. He attended medical school at the University of California, San Francisco and simultaneously pursued graduate work in Bioengineering at the University of California, Berkeley focusing on technology issues in medicine. He completed his residency at Harbor–UCLA Medical Center in the Department of Emergency Medicine.
Lenny Herold Co-Founder, Corsis
Lenny has amassed over 25 years of experience in the technology industry, honing his skills while managing infrastructure at scale for numerous large media companies in New York City. He has managed both co-located and cloud-based environments at scale, navigated numerous mergers and acquisitions, datacenter consolidations, and high-profile deployments. He's passionate about automation, configuration management and virtualization.
In 2010, Lenny co-founded Corsis, a highly regarded technology advisory firm that provides services to the private equity sector. At Corsis, he played a critical role in developing the methodology the company utilized to assess and gauge the effectiveness of technology systems during due diligence. He spearheaded hundreds of evaluations covering diverse areas such as architecture, software development, infrastructure, and security. In 2020, Falfurrias Capital Partners acquired Corsis.
Lenny earned a B.S. in Telecommunications from the University of Florida.
Christine Hurtubise VP AI/ML Engineering FIS and Former Head of Data Science and Risk Orum.io,
Christine has led teams that create cutting-edge cloud data platforms and analytics solutions for the financial services industry. As the VP of AI/ML Engineering at FIS, a global leader in FinTech and payments, she has overseen the development and deployment of AI at scale. Her mission is to enable data-driven decision making and innovation across the organization and its clients. Christine has led data science departments in FinTech startups, scaling programs from 0-1 and bringing multiple data and ML products to market. As part of this, she has created agentic workflows for our regional and community bankers.
Christine is an active angel investor and advisor for data-driven FinTech startups. Through the Angel Track program at First Round Capital, one of the most prominent seed-stage venture capital firms, she invests in and supports early-stage companies that leverage data and technology to transform the financial sector. Christine has a portfolio of over 10 companies, ranging from payment platforms to credit scoring solutions. Christine is passionate about using her expertise and network to help entrepreneurs and founders achieve their vision and scale their impact.
Christine earned a B.S. in Mathematics and French from the University of Pennsylvania.
Ramesh Mandava CEO & Head of AI/ML, Data Sciences & Analytics OneVector and Former Senior Technical Product Manager Amazon,
Ramesh Mandava is an AI/ML and data analytics executive with over 20 years of experience helping Fortune 50 companies define and execute strategies that unlock measurable business value. He has led several transformative greenfield AI/ML and data analytics initiatives, including global cash flow forecasting at GE, improving liquidity planning and reducing peak short-term debt by 60%; optimizing AWS data center supply chains through an $860M program that delivered $105M in annual savings; and driving product promotion strategies at Amazon Devices that safeguarded $65M in pricing integrity.
Currently, as co-founder of OneVector Technologies, Ramesh partners with life sciences & biotech companies to design and implement AI solutions that modernize IT landscapes, improve quality compliance, and responsibly implement agentic technologies to reduce manual workloads and surface insights across large collections of documents and data. He is also leading the development of a proprietary GenAI platform for pharmacovigilance, using NLP and LLM technologies responsibly to process adverse event signals, accelerate insights from large volumes of regulated data, and streamline report generation that reduces manual review times and improves decision-making across compliance and quality functions.
Ramesh is recognized for leveraging lean and agile principles to identify, prioritize, and operationalize high value AI opportunities that balance feasibility with business impact, enabling leadership teams to make confident decisions and unlock maximum value. A proven people leader and trusted advisor to C-suite executives, he has built and managed global teams, directed multimillion-dollar technology budgets, and consistently delivered digital transformation efforts that scale.
Ramesh earned a B.S. in Computer Science and Engineering from Madras University and an M.S. in Computer Science from Illinois Institute of Technology.